Abstract
With the implementation of anti-HER2 therapies in clinical practice, the OS of patients with HER2(+) breast carcinoma significantly improves. The aim of this retrospective analysis is to asses the prognostic value of dynamic HER2 status conversion among the patients with metastatic disease, treated in our institution.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
